pre-IPO PHARMA

slayback-pharma PRESS RELEASE ARCHIVE

Feb 4, 2021

Slayback Pharma announces launch of Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg, generic equivalent of Taytulla


Dec 18, 2020

Slayback Pharma announces FDA approval of Merzee, generic equivalent of Taytulla with a Competitive Generic Therapy (CGT) Designation


Dec 7, 2020

Slayback Pharma Appoints Dr Sumitra Pillai as Head of RandD


Sep 2, 2020

Slayback Pharma announces approval of Icatibant Injection 30 mg/3 ml (10 mg/ ml), generic equivalent of Firazyr.


Aug 17, 2020

Slayback Pharma Appoints Lori A. Hoffman as Head of Alliance Management



Jan 6, 2020

Slayback Pharma announces investment of $50 million by The Everstone Group


Dec 10, 2019

Slayback Pharma announces approval and immediate launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in 200 mcg/ 50 mL and 400 mcg/ 100 mL (4 mcg/mL) vials, generic equivalent of Precedex™ 4 mcg/ mL


Mar 25, 2019

Slayback Pharma announces approval of Hydroxyprogesterone Caproate Injection, USP 250 mg/ 1 mL in a single-dose vial, generic equivalent of Makena® Injection 250 mg/ 1 mL


Jan 21, 2019

Slayback Pharma announces launch of Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 mL in a multi-dose vial, the first generic equivalent of Makena Injection 1,250 mg/ 5 mL multi-dose vial


Jan 2, 2019

Slayback Pharma announces FDA approval of Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 mL in a multi-dose vial, the first generic equivalent of Makena® Injection 1,250 mg/ 5 mL multi-dose vial



Jul 24, 2018

Slayback Pharma Appoints Dr Girish Jain as Head of Global R&D


Jul 16, 2018

Slayback Pharma Appoints Joan Janulis as Head of Global Regulatory Affairs


Jun 29, 2018

Ajay Singh of Slayback Pharma wins Ernst and Young's Entrepreneur Of The Year® 2018 Award in Life Sciences Category in New Jersey


Apr 25, 2018

Ajay Singh of Slayback Pharma named Ernst and Young's Entrepreneur Of The Year® 2018 Award Finalist in New Jersey


Jun 27, 2017

Slayback Pharma Appoints Patrick McIntosh as Head of Commercial Operations



Jan 5, 2017

Slayback Pharma Announces $60 Million in New Financing by KKR


Jan 5, 2017

Slayback Pharma Announces $60 Million in New Financing by KKR


Dec 24, 2016

Slayback Pharma announces the final approval and launch of Generic Zovirax (Acyclovir) Ointment 5%


Dec 23, 2016

Slayback Pharma announces the final approval and launch of Generic Zovirax (Acyclovir) Ointment 5%


Google Analytics Alternative